Why the study?
Cancer therapy-related cardiac dysfunction affects around 10% of chemotherapy-treated patients, presenting a significant clinical challenge.
Does cardioprotective medical therapy and cardiac rehabilitation improve cardiac function in a patient with symptomatic cancer therapy-related cardiac dysfunction?
Does cardioprotective medical therapy and cardiac rehabilitation improve cardiac function in a patient with symptomatic cancer therapy-related cardiac dysfunction?
Prompt initiation of guideline-directed medical therapy and cardiac rehabilitation can effectively improve cardiac function and symptoms in patients who develop cancer therapy-related cardiac dysfunction.
Echocardiography and biomarkers aid CTRCD monitoring; leaves open optimal recovery strategies pending prospective trials.
Chemotherapy has markedly improved cancer outcomes, yet cancer therapy-related cardiac dysfunction (CTRCD) poses a significant challenge, affecting around 10% of patients. CTRCD can be asymptomatic or present with heart failure symptoms. Multimodality imaging, particularly echocardiography, remains pivotal for monitoring cardiac function. Potential biomarkers for CTRCD assessment include troponin and B-type natriuretic peptide. Pharmacological interventions, such as dexrazoxane, angiotensin-converting enzyme inhibitors, and statins, play a crucial role in primary prevention and mitigating cardiotoxicity alongside cardiac rehabilitation programs. Thus, a comprehensive approach is essential for optimal cardiac recovery and improved patient outcomes.
No takes yet. Share an insight, caveat, or question.
Martinez‐Dominguez et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: